JBC:发现新的p53-p21通路的调节因子

2012-04-20 Deepblue 生物谷

TBP(TATA结合蛋白)是转录因子TFⅡD的组分之一。TBP类似蛋白(TLP)能够增强基因表达,研究发现它与细胞发育、细胞周期调控及细胞凋亡息息相关。近日,来自日本千叶大学的研究人员发现,TLP介导了p53-p21通路的调节作用。相关论文发表在4月18日的The Journal of Biological Chemistry。 TLP过表达的人类细胞,尤其是在含有p53的细胞,生长速率下降,G

TBP(TATA结合蛋白)是转录因子TFⅡD的组分之一。TBP类似蛋白(TLP)能够增强基因表达,研究发现它与细胞发育、细胞周期调控及细胞凋亡息息相关。近日,来自日本千叶大学的研究人员发现,TLP介导了p53-p21通路的调节作用。相关论文发表在4月18日的The Journal of Biological Chemistry

TLP过表达的人类细胞,尤其是在含有p53的细胞,生长速率下降,G1期细胞比例增加。研究发现,TLP刺激了生长有关的基因包括p21(p21Waf1/Cip1)的表达。通过启动子荧光素酶报告基因分析发现,TLP介导了p21上游启动子的激活。

p53结合序列定位于p21上游启动子,而p53自身也与TLP介导的转录激活有关。他们发现,TLP与p53彼此结合,协同的增强了上游启动子的活性。而且,TLP能够特异性的激活内源性上游启动子的转录,p53也参与了该激活作用。

依托泊苷是一种细胞周期特异性抗肿瘤药物。使用依托泊苷处理后,也导致了上游启动子激活以及核内TLP及p53的积聚。结果表明,上游启动子与内源性TLP及p53有关,TLP能够增强p53招募。

该研究表明,TLP介导了由p53控制的p21上游启动子的转录激活。由于p53与癌症发生密切相关,TLP有可能也会成为新的癌症治疗靶点。

doi: 10.1074/jbc.M112.369629
PMC:
PMID:

TATA-binding protein (TBP)-like protein is required for p53-dependent transcriptional activation of an upstream promoter of the p21Waf1/Cip1 gene

Hidefumi Suzuki, Ryo Ito, Kaori Ikeda and Taka-aki Tamura.

TBP-like protein (TLP) is involved in development, checkpoint, and apoptosis through potentiation of gene expression.TLP-overexpressing human cells, especially p53-containing cells, exhibited a decreased growth rate and increased proportion of G1-phase cells.TLP stimulated expression of several growth-related genes including p21 (p21Waf1/Cip1). TLP-mediated activation of the p21 upstream promoter in cells was shown by a luciferase promoter reporter assay.The p53-binding sequence located in the p21 upstream promoter and p53 itself are required for TLP-mediated transcriptional activation.TLP and p53 bound to each other, and synergistically enhanced activity of the upstream promoter.TLP specifically activated transcription from the endogenous upstream promoter, and p53 was required for this activation.Etoposide treatment also resulted in activation of the upstream promoter as well as nuclear accumulation of TLP and p53.Moreover, the upstream promoter was associated with endogenous p53 and TLP, and the p53 recruitment was enhanced by TLP.The results of the present study suggest that TLP mediates p53-governed transcriptional activation of the p21 upstream promoter.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1072024, encodeId=638910e2024cd, content=已阅,受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Sat Nov 20 10:02:21 CST 2021, time=2021-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036355, encodeId=7f212036355f6, content=<a href='/topic/show?id=0c901025932' target=_blank style='color:#2F92EE;'>#JBC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10259, encryptionId=0c901025932, topicName=JBC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Wed Jan 30 14:13:00 CST 2013, time=2013-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786020, encodeId=21261e86020e9, content=<a href='/topic/show?id=48f613605c4' target=_blank style='color:#2F92EE;'>#p21#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13605, encryptionId=48f613605c4, topicName=p21)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Wed Feb 06 02:13:00 CST 2013, time=2013-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1969246, encodeId=4a90196924664, content=<a href='/topic/show?id=10e09205572' target=_blank style='color:#2F92EE;'>#调节因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92055, encryptionId=10e09205572, topicName=调节因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Wed Feb 06 01:13:00 CST 2013, time=2013-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372336, encodeId=facb13e233636, content=<a href='/topic/show?id=9d861362e53' target=_blank style='color:#2F92EE;'>#p53#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13627, encryptionId=9d861362e53, topicName=p53)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5d70341, createdName=zhishijing, createdTime=Sun Apr 22 10:13:00 CST 2012, time=2012-04-22, status=1, ipAttribution=)]
    2021-11-20 湘雅科教

    已阅,受益匪浅。

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1072024, encodeId=638910e2024cd, content=已阅,受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Sat Nov 20 10:02:21 CST 2021, time=2021-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036355, encodeId=7f212036355f6, content=<a href='/topic/show?id=0c901025932' target=_blank style='color:#2F92EE;'>#JBC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10259, encryptionId=0c901025932, topicName=JBC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Wed Jan 30 14:13:00 CST 2013, time=2013-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786020, encodeId=21261e86020e9, content=<a href='/topic/show?id=48f613605c4' target=_blank style='color:#2F92EE;'>#p21#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13605, encryptionId=48f613605c4, topicName=p21)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Wed Feb 06 02:13:00 CST 2013, time=2013-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1969246, encodeId=4a90196924664, content=<a href='/topic/show?id=10e09205572' target=_blank style='color:#2F92EE;'>#调节因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92055, encryptionId=10e09205572, topicName=调节因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Wed Feb 06 01:13:00 CST 2013, time=2013-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372336, encodeId=facb13e233636, content=<a href='/topic/show?id=9d861362e53' target=_blank style='color:#2F92EE;'>#p53#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13627, encryptionId=9d861362e53, topicName=p53)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5d70341, createdName=zhishijing, createdTime=Sun Apr 22 10:13:00 CST 2012, time=2012-04-22, status=1, ipAttribution=)]
    2013-01-30 lily1616
  3. [GetPortalCommentsPageByObjectIdResponse(id=1072024, encodeId=638910e2024cd, content=已阅,受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Sat Nov 20 10:02:21 CST 2021, time=2021-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036355, encodeId=7f212036355f6, content=<a href='/topic/show?id=0c901025932' target=_blank style='color:#2F92EE;'>#JBC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10259, encryptionId=0c901025932, topicName=JBC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Wed Jan 30 14:13:00 CST 2013, time=2013-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786020, encodeId=21261e86020e9, content=<a href='/topic/show?id=48f613605c4' target=_blank style='color:#2F92EE;'>#p21#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13605, encryptionId=48f613605c4, topicName=p21)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Wed Feb 06 02:13:00 CST 2013, time=2013-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1969246, encodeId=4a90196924664, content=<a href='/topic/show?id=10e09205572' target=_blank style='color:#2F92EE;'>#调节因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92055, encryptionId=10e09205572, topicName=调节因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Wed Feb 06 01:13:00 CST 2013, time=2013-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372336, encodeId=facb13e233636, content=<a href='/topic/show?id=9d861362e53' target=_blank style='color:#2F92EE;'>#p53#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13627, encryptionId=9d861362e53, topicName=p53)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5d70341, createdName=zhishijing, createdTime=Sun Apr 22 10:13:00 CST 2012, time=2012-04-22, status=1, ipAttribution=)]
    2013-02-06 tulenzi
  4. [GetPortalCommentsPageByObjectIdResponse(id=1072024, encodeId=638910e2024cd, content=已阅,受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Sat Nov 20 10:02:21 CST 2021, time=2021-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036355, encodeId=7f212036355f6, content=<a href='/topic/show?id=0c901025932' target=_blank style='color:#2F92EE;'>#JBC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10259, encryptionId=0c901025932, topicName=JBC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Wed Jan 30 14:13:00 CST 2013, time=2013-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786020, encodeId=21261e86020e9, content=<a href='/topic/show?id=48f613605c4' target=_blank style='color:#2F92EE;'>#p21#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13605, encryptionId=48f613605c4, topicName=p21)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Wed Feb 06 02:13:00 CST 2013, time=2013-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1969246, encodeId=4a90196924664, content=<a href='/topic/show?id=10e09205572' target=_blank style='color:#2F92EE;'>#调节因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92055, encryptionId=10e09205572, topicName=调节因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Wed Feb 06 01:13:00 CST 2013, time=2013-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372336, encodeId=facb13e233636, content=<a href='/topic/show?id=9d861362e53' target=_blank style='color:#2F92EE;'>#p53#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13627, encryptionId=9d861362e53, topicName=p53)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5d70341, createdName=zhishijing, createdTime=Sun Apr 22 10:13:00 CST 2012, time=2012-04-22, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1072024, encodeId=638910e2024cd, content=已阅,受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Sat Nov 20 10:02:21 CST 2021, time=2021-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036355, encodeId=7f212036355f6, content=<a href='/topic/show?id=0c901025932' target=_blank style='color:#2F92EE;'>#JBC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10259, encryptionId=0c901025932, topicName=JBC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Wed Jan 30 14:13:00 CST 2013, time=2013-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786020, encodeId=21261e86020e9, content=<a href='/topic/show?id=48f613605c4' target=_blank style='color:#2F92EE;'>#p21#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13605, encryptionId=48f613605c4, topicName=p21)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Wed Feb 06 02:13:00 CST 2013, time=2013-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1969246, encodeId=4a90196924664, content=<a href='/topic/show?id=10e09205572' target=_blank style='color:#2F92EE;'>#调节因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92055, encryptionId=10e09205572, topicName=调节因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Wed Feb 06 01:13:00 CST 2013, time=2013-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372336, encodeId=facb13e233636, content=<a href='/topic/show?id=9d861362e53' target=_blank style='color:#2F92EE;'>#p53#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13627, encryptionId=9d861362e53, topicName=p53)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5d70341, createdName=zhishijing, createdTime=Sun Apr 22 10:13:00 CST 2012, time=2012-04-22, status=1, ipAttribution=)]
    2012-04-22 zhishijing

相关资讯

J Cell Bio:一个基因能遏制乳腺癌

近日,日本一个研究小组日前发布研究成果说,具有肿瘤抑制作用的乳腺癌易感基因BRCA1除可通过修复染色体异常来遏制乳腺癌和卵巢癌外,还能通过生成小核糖核酸来遏制癌症。这一成果可协助研究人员开发出新治疗药物。 乳腺癌易感基因BRCA1是近年来发现的一个肿瘤抑制基因,它的结构和功能变化与家族型乳腺癌和卵巢癌的发生有关。研究证实,BRCA1基因发生突变的人在40岁以前得乳腺癌的概率高达19%。&

肿瘤细胞免疫治疗策略

     郭亚军教授           相关幻灯资料   肿瘤细胞免疫治疗是继手术、放疗、化疗三大传统手段后的新支柱性治疗手段,最大的优势在于个体性、安全性、靶向性和高效性。肿瘤细胞免疫疗法并不能完全代替传统的治疗方法,但是可以起到辅助治疗作用,在手术、放化疗后获释患者放化疗间歇期使用肿瘤细胞免疫疗法效果较为显著。4月13日,在全国第五

PTPMeg2调节STAT3抑制乳腺癌

在最新一期国际权威乳腺癌杂志Breast Cancer Research上发表了清华大学常智杰教授研究组和孟坤博士合作的研究成果“Protein tyrosine phosphatase Meg2 dephosphorylates signal transducer and activator of transcription 3 and suppresses tumor growth

PLoS ONE:miR-205可能是子宫内膜癌预后标记物

microRNAs已经被发现是基因表达的重要调控因子,它们改变基因表达的作用与癌症发生及肿瘤增殖密切相关。因此,microRNAs能够成为潜在的癌症标记物及治疗靶点。 虽然已有的证据表明了microRNAs的异常表达与子宫内膜癌有关,但是microRNAs对子宫内膜癌的预后意义有关的数据仍然有限。 近日,美国纽约州立石溪大学的研究人员做了一项关于microRNAs的研究。这项研究的目的在于,通

JBC:研究发现胆固醇有抗癌功效

西蒙·弗雷泽大学研究人员最近发现胆固醇有减缓或阻止癌细胞生长的作用。相关研究论文发表在Journal of Biological Chemistry杂志上。 科学家们一直试图了解胆固醇如何从细胞内部移动到细胞表面,进而强化细胞外膜。 SFU分子生物学和生物化学副教授Chris Beh解释说:我们假设ORPs以脂蛋白结合并通过血液将脂肪运送出细胞外类似的方式绑定以及运输胆固醇进入细胞内。 Be

Nat Commun:日研究发现放疗后癌细胞转移机制

4月18日,日本京都大学的研究小组发布报告说,他们利用小鼠试验,发现了经放射治疗后癌细胞转移的机制,并可通过遏制这类细胞的转移,防止癌症的复发,有望开发出新的癌症疗法。相关论文刊登在英国《自然—通讯》(Nature Communications)上。 放射治疗是与手术、化疗并列的癌症三大治疗手段之一,这一疗法利用各种不同能量的射线照射肿瘤,以抑制和杀灭癌细胞。放疗可单独使用,也可与手术、